CICC Assists Henlius in Listing on the Main Board of the Stock Exchange of Hong Kong

Shanghai Henlius Biotech, INC. (“Henlius” or the “Company”, Code: 2696.HK) is successfully listed on the Main Board of HKEX on September 25th, 2019. CICC acted as the role of leading sponsor and leading global coordinator. The pre-green shoe offering size is approximately US$409 million, and the post-green shoe offering size is approximately US$471 million (assuming the Over-allotment Option is fully exercised). It is the largest IPO on the main board of HKEX measured by scale of capital raised since 2019 in biopharmaceutical industry under Chapter 18A. Meanwhile, the Company is the Chinese biopharmaceutical company with highest market-cap at the time of IPO.

Henlius is a leading biopharmaceutical company in China with the vision to offer high-quality, affordable and innovative drugs for patients worldwide with a focus on oncology and autoimmune diseases. Since its inception in 2010, the Company has built an integrated and productive global R&D platform with three facilities in Shanghai, Taipei and California. Its three R&D centers closely collaborate with each other to ensure a highly productive and cost-efficient R&D process. In line with its product development strategy, the Company has established and continues to expand a comprehensive product pipeline of both biosimilars and bio-innovative drugs. It has also launched immuno-oncology combination therapies based on its self-developed PD-1 and PD-L1 mAb candidates, developed a diversified mAb and immuno-oncology combination therapy pipeline, and established an integrated platform covering research, development and commercialization.

As of today, one product of Henlius has been successfully launched to the market and two candidates have been submitted to the NMPA for marketing approval.  The company has conducted or is conducting over 20 clinical trials. Among which, HLX01 (rituximab injection), the Company’s first product, has been granted approval by the NMPA in February 2019 as the first biosimilar approved in China. HLX03 (A Humira (adalimumab) biosimilar) and HLX02 (A Herceptin (trastuzumab) biosimilar) have received New Drug Application (NDA) acceptances from NMPA, and are currently under priority review. HLX02 is the first biosimilar developed in China to enter a multi-jurisdictional Phase 3 clinical trial in China, Poland, Ukraine and the Philippines, with MAA accepted by the EMA in June 2019. In addition, the Company has launched various immuno-oncology combination therapies in relation to HLX10 and its self-developed candidates HLX04 (bevacizumab biosimilar), HLX07 (an EGFR inhibitor) and other mAb candidates in combination with chemotherapy, and commenced a number of clinical trials worldwide.

During the execution of this deal, CICC had led the work of obtaining approval from CSRC and HKEX and coordinated each work stream to ensure the overall progress of the execution.

Although the HK market faced fluctuations during global offering, acting as Leading Sponsor and Leading Global Coordinator, CICC explored the client’s demands thoroughly. CICC introduced a large number of demands as of cornerstone investors and international placements, including high-quality long funds, well known hedge funds, healthcare specialists and private wealth management clients, and ranked top among all banks. CICC’s contribution was highly recognized by the Company.

With rich execution experience and strong comprehensive service capabilities, CICC assists Henlius to become the company with the highest offering size among all the biotech companies listed in Hong Kong since 2019, as well as the highest market capitalization at the time of listing among all listed pre-revenue Chinese biotech companies.

As a leading investment bank with “Chinese Roots, International Reach”, CICC will continue to utilize its capital market expertise as well as its seamless cooperation of onshore and offshore businesses to provide continuous support to our customers in terms of introduction of global investors, reaching international capital market, and business development.